Krishna Institute of Medical Sciences Limited Stocks

649.85Last Updated 10.02.2026

Issuer Rating

5/7

Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

₹ 2.85B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
649.85
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services....

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of KIMS.NS is 725 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks